Erasca (ERAS) Return on Capital Employed (2021 - 2026)
Erasca (ERAS) reported Return on Capital Employed of 72.93% for Q1 2026, down 3470.0% on a YoY basis from 2.16% in Q1 2025, and down 96.55% quarter-over-quarter from 37.1% in Q4 2025.
Erasca (ERAS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Erasca has reported Return on Capital Employed for 6 years, with the latest figure at 72.93% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 3470.0% year-over-year to 72.93%; the trailing twelve-month figure through Mar 2026 stood at 72.93% (down 3470.0% YoY), and the FY2025 full-year result was 33.48%, up 953.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 72.93%, down from 37.1% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.36% in Q1 2022, with the low at 72.93% in Q1 2026.
- Historically, Return on Capital Employed has averaged 43.36% across 5 years, with a median of 37.13% in 2023.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 2519 bps — and 2026, when it sank 3470 bps.
- Erasca's Return on Capital Employed stood at 57.28% in 2022, then surged by 35 bps to 37.13% in 2023, then rose by 0 bps to 37.08% in 2024, then fell by 0 bps to 37.1% in 2025, then sank by 97 bps to 72.93% in 2026.
- The last three Return on Capital Employed figures came in at 72.93% (Q1 2026), 37.1% (Q4 2025), and 35.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Erasca | 4.16 Bn | 3.92 Bn | - | -72.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -72.93% |
| Dec 31, 2025 | -37.10% |
| Sep 30, 2025 | -35.63% |
| Jun 30, 2025 | -34.11% |
| Mar 31, 2025 | -38.22% |
| Dec 31, 2024 | -37.08% |
| Sep 30, 2024 | -35.74% |
| Jun 30, 2024 | -41.41% |
| Mar 31, 2024 | -40.68% |
| Dec 31, 2023 | -37.13% |
| Sep 30, 2023 | -60.93% |
| Jun 30, 2023 | -57.57% |
| Mar 31, 2023 | -53.25% |
| Dec 31, 2022 | -57.28% |
| Sep 30, 2022 | -33.60% |
| Jun 30, 2022 | -34.15% |
| Mar 31, 2022 | -30.36% |
| Dec 31, 2021 | -25.72% |
| Sep 30, 2021 | -46.40% |